Aurinia Pharmaceuticals Inc

NASDAQ:AUPH   3:59:53 PM EDT
20.94
+1.56 (+8.05%)
4:12:21 PM EDT: $20.93 -0.01 (-0.05%)
Mergers / Acquisitions

Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune Diseases

Published: 08/17/2021 10:36 GMT
Aurinia Pharmaceuticals Inc (AUPH) - Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases.
Aurinia Acquires Novel Pipeline Assets Targeting Autoimmune and Kidney-related Diseases.
Aurinia Pharmaceuticals Inc - Assets Expand Immunology Portfolio to Include B-cell Therapy (baff/april) and Macrophage Modulation.
Aurinia Pharmaceuticals Inc - Aur200, Was Acquired by Purchasing All of Common Stock of Thunderbolt Pharma.
Aurinia Pharmaceuticals Inc - Aur300, Was Secured Through a Global Licensing and Research Agreement With Riptide Bioscience.